Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (17)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Smyth, J.
Right arrow Articles by Hanauske, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Smyth, J.
Right arrow Articles by Hanauske, A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 12:509-511, 2001
© 2001 European Society for Medical Oncology

research-article

Activity of the dolastatin analogue, LU103793, in malignant melanoma

J. Smyth1,, M. E. Boneterre2, J. Schellens3, H. Calvert4, G. Greim5, J. Wanders6 and A. Hanauske7

1ICRFMedical Oncology Unit, Western General Hospital Edinburgh, UK
2Centre Oscar Lambret Lille, France
3Antoni van Leeuwenhoeh Ziekenhuis, Department of Medical Oncology Amsterdam. The Netherlands
4Department of Oncology, Newcastle General Hospital Newcastle-Upon-Tyne, UK
5Klinikum Nürnberg, 5. Medizinische Klinik Nurnberg, Germany
6EORTC-NDDO Academic Hospital. Vrije Universiteit Amsterdam, The Netherlands
7Technische Universität, Munchen, Germany

Correspondence to: Prof J F Smyth, ICRF Medical Oncology Unit, MRC Building, Western General Hospital, Crewe Road, Edinburgh EH4 2XU, UK, E-mail j.smyth{at}icrf.icnet.uk

LU103793, a synthetic analogue of dolastatin 15, showed interesting pre-clinical activity in melanoma xenografts In this phase II multicentre trial, 80 chemotherapy-naive patients with metastatic melanoma received a total of 218 cycles of treatment The response rate showed one complete and three partial responses of median duration six months (range 3–9 I) Toxicity was moderate, mostly haematological (neutropenia grade 4 in 16%, grade 3 in 3%) There were no significant problems with hypertension or other non-haematological toxicities

dolastatin, LU103793, melanoma, phase II


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Molecular Cancer TherapeuticsHome page
T. L. Simmons, E. Andrianasolo, K. McPhail, P. Flatt, and W. H. Gerwick
Marine natural products as anticancer drugs
Mol. Cancer Ther., February 1, 2005; 4(2): 333 - 342.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
M. L. Amador, J. Jimeno, L. Paz-Ares, H. Cortes-Funes, and M. Hidalgo
Progress in the development and acquisition of anticancer agents from marine sources
Ann. Onc., November 1, 2003; 14(11): 1607 - 1615.
[Full Text] [PDF]

Home page
 Cancer Res.Home page
F. Loganzo, C. M. Discafani, T. Annable, C. Beyer, S. Musto, M. Hari, X. Tan, C. Hardy, R. Hernandez, M. Baxter, et al.
HTI-286, a Synthetic Analogue of the Tripeptide Hemiasterlin, Is a Potent Antimicrotubule Agent that Circumvents P-Glycoprotein-mediated Resistance in Vitro and in Vivo
Cancer Res., April 15, 2003; 63(8): 1838 - 1845.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
D. J. Kerr
Pride and judgement: the Annals of Oncology prizes
Ann. Onc., June 1, 2002; 13(6): 817 - 818.
[Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.